New drug tested to boost brain speed in early Alzheimer's

NCT ID NCT05619692

Completed Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested whether an investigational drug called SAGE-718 could improve cognitive performance, specifically processing speed, in people with early-stage Alzheimer's disease or mild cognitive impairment. 174 participants were randomly assigned to receive either the drug or a placebo to see if it helped them perform certain mental tasks faster and better. The main goal was to see if the drug could ease this specific symptom of the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Sage Investigational Site

Gilbert, Arizona, 85297, United States
Sage Investigational Site

Phoenix, Arizona, 85297, United States
Sage Investigational Site

Lafayette, California, 94549, United States
Sage Investigational Site

Long Beach, California, 90808, United States
Sage Investigational Site

Redlands, California, 92374, United States
Sage Investigational Site

San Diego, California, 92123, United States
Sage Investigational Site

Sherman Oaks, California, 91403, United States
Sage Investigational Site

Englewood, Colorado, 80120, United States
Sage Investigational Site

Hollywood, Florida, 33024, United States
Sage Investigational Site

Jacksonville, Florida, 32256, United States
Sage Investigational Site

Miami, Florida, 33155, United States
Sage Investigational Site

Palm Beach Gardens, Florida, 33410, United States
Sage Investigational Site

Pensacola, Florida, 32504, United States
Sage Investigational Site

Tampa, Florida, 33609, United States
Sage Investigational Site

Winter Park, Florida, 32789, United States
Sage Investigational Site

Decatur, Georgia, 30030, United States
Sage Investigational Site

Savannah, Georgia, 31404, United States
Sage Investigational Site

Honolulu, Hawaii, 96817, United States
Sage Investigational Site

Meridian, Idaho, 83642, United States
Sage Investigational Site

Chicago, Illinois, 60640, United States
Sage Investigational Site

Charlestown, Massachusetts, 02129, United States
Sage Investigational Site

Methuen, Massachusetts, 01844, United States
Sage Investigational Site

Chesterfield, Missouri, 63005, United States
Sage Investigational Site

Papillion, Nebraska, 68046, United States
Sage Investigational Site

Toms River, New Jersey, 08755, United States
Sage Investigational Site

Albuquerque, New Mexico, 87109, United States
Sage Investigational Site

Brooklyn, New York, 11229, United States
Sage Investigational Site

Buffalo, New York, 14203, United States
Sage Investigational Site

Staten Island, New York, 10312, United States
Sage Investigational Site

Raleigh, North Carolina, 27607, United States
Sage Investigational Site

Abington, Pennsylvania, 19001, United States
Sage Investigational Site

Memphis, Tennessee, 38119, United States
Sage Investigational Site

Nashville, Tennessee, 37212, United States
Sage Investigational Site

Austin, Texas, 78731, United States
Sage Investigational Site

Dallas, Texas, 75231, United States
Sage Investigational Site

Houston, Texas, 77030, United States
Sage Investigational Site

Fairfax, Virginia, 22031, United States
Sage Investigational Site

Bayamón, 00961, Puerto Rico
Sage Investigational Site

Rio Piedras, 00935, Puerto Rico

Conditions

Explore the condition pages connected to this study.

ALZHEIMER S DISEASE MILD COGNITIVE IMPAIRMENT MILD DEMENTIA